MX2021006360A - Composicion farmaceutica de anticuerpo cd40 y uso de la misma. - Google Patents

Composicion farmaceutica de anticuerpo cd40 y uso de la misma.

Info

Publication number
MX2021006360A
MX2021006360A MX2021006360A MX2021006360A MX2021006360A MX 2021006360 A MX2021006360 A MX 2021006360A MX 2021006360 A MX2021006360 A MX 2021006360A MX 2021006360 A MX2021006360 A MX 2021006360A MX 2021006360 A MX2021006360 A MX 2021006360A
Authority
MX
Mexico
Prior art keywords
pharmaceutical composition
antibody pharmaceutical
antibody
present
excipients
Prior art date
Application number
MX2021006360A
Other languages
English (en)
Inventor
Jianjian Yang
Hao Li
Jiahua Jiang
Xun Liu
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2021006360A publication Critical patent/MX2021006360A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

La presente invención provee una composición farmacéutica que comprende un anticuerpo CD40 o un fragmento de unión a antígeno del mismo y una solución amortiguadora de ácido acético-acetato de sodio, y el uso de la misma; además, la composición farmacéutica puede contener azúcar, un agente tensoactivo no iónico y otros excipientes; la composición farmacéutica de la presente invención muestra buena estabilidad del anticuerpo.
MX2021006360A 2018-11-30 2019-11-29 Composicion farmaceutica de anticuerpo cd40 y uso de la misma. MX2021006360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811448238 2018-11-30
PCT/CN2019/121985 WO2020108621A1 (zh) 2018-11-30 2019-11-29 一种cd40抗体药物组合物及其用途

Publications (1)

Publication Number Publication Date
MX2021006360A true MX2021006360A (es) 2021-08-11

Family

ID=70852664

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006360A MX2021006360A (es) 2018-11-30 2019-11-29 Composicion farmaceutica de anticuerpo cd40 y uso de la misma.

Country Status (10)

Country Link
EP (1) EP3939998A4 (es)
JP (1) JP2022513671A (es)
KR (1) KR20210097750A (es)
CN (1) CN112839961B (es)
AU (1) AU2019388931A1 (es)
BR (1) BR112021010414A2 (es)
CA (1) CA3121291A1 (es)
MX (1) MX2021006360A (es)
TW (1) TW202021620A (es)
WO (1) WO2020108621A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3232171A1 (en) * 2021-09-24 2023-03-30 Zhenzhen Lu Anti-cd40 antibody and use thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10308991A (ja) 1997-05-07 1998-11-17 Mitsubishi Electric Corp スピーカー取付構造
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
DE60143535D1 (de) 2000-10-02 2011-01-05 Novartis Vaccines & Diagnostic Humane antikörper gegen cd40
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
WO2006073443A2 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
BRPI0610470A2 (pt) 2005-05-26 2010-06-22 Seattle Genetics Inc anticorpo isolado ou fragmento de ligação a antìgeno que especificamente se liga a cd40 humano, kit, composição farmacêutica, e, polinucleotìdeo isolado
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
WO2011123489A2 (en) 2010-03-31 2011-10-06 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies
CN106977604A (zh) 2011-04-21 2017-07-25 百时美施贵宝公司 拮抗cd40之抗体多肽
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
GB201322583D0 (en) 2013-12-19 2014-02-05 Alligator Bioscience Ab Antibodies
WO2016115475A1 (en) * 2015-01-18 2016-07-21 Biogen Ma Inc. Anti-cd40 antibody formulations
CA2987051A1 (en) 2015-05-29 2016-12-08 Abbvie Inc. Anti-cd40 antibodies and uses thereof
US20180142030A1 (en) 2015-06-29 2018-05-24 Bristol-Myers Squibb Company Antibodies to cd40
PL3344655T3 (pl) * 2015-09-01 2024-02-19 Boehringer Ingelheim International Gmbh Zastosowanie przeciwciał anty-cd40 w leczeniu toczniowego zapalenia nerek
SI3307322T1 (sl) 2015-09-04 2021-08-31 Primatope Therapeutics Inc. Humanizirana protitelesa proti CD40 in njihove uporabe
EP3632932A4 (en) * 2017-06-01 2021-08-18 Jiangsu Hengrui Medicine Co. Ltd. ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THIS ANTIGEN AND ASSOCIATED MEDICAL USE

Also Published As

Publication number Publication date
AU2019388931A1 (en) 2021-07-15
CA3121291A1 (en) 2020-06-04
CN112839961A (zh) 2021-05-25
WO2020108621A1 (zh) 2020-06-04
EP3939998A4 (en) 2022-08-10
EP3939998A1 (en) 2022-01-19
TW202021620A (zh) 2020-06-16
KR20210097750A (ko) 2021-08-09
JP2022513671A (ja) 2022-02-09
BR112021010414A2 (pt) 2021-09-08
CN112839961B (zh) 2023-04-04

Similar Documents

Publication Publication Date Title
MY195465A (en) PD-L1 Antibody Pharmaceutical Composition and use Thereof
GEP20217249B (en) Stable liquid pharmaceutical preparation
WO2018042343A3 (en) Compounds that inhibit 3c and 3cl proteases and methods of use thereof
MX2018003306A (es) Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina.
MX2020007799A (es) Inhibidores de cinasa no derrepresible de control de aminoacido general 2 (gcn2) y sus usos.
EP4039706A4 (en) ANTIBODIES TARGETING CLDN18.2, METHOD FOR PREPARATION AND USE
EP3753951A4 (en) ANTI-B7-H4 ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
MX2020000582A (es) Composicion farmaceutica de anticuerpos sost y usos de la misma.
PH12020551716A1 (en) Anti-ror antibody constructs
AU2019206958A1 (en) PD-L1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
PH12019501314A1 (en) Pharmaceutical combination comprising a t-type calcium channel blocker
ZA201908610B (en) Il-15 protein complex pharmaceutical composition and uses thereof
MX2021001272A (es) Composiciones de bismuto-tiol y metodos de uso.
EP3831944A4 (en) ANTI-MMR1 MONOCLONAL ANTIBODY, ASSOCIATED FUNCTIONAL FRAGMENT, GENE, COMPOSITION OF DRUG ADMINISTRATION AND PHARMACEUTICAL COMPOSITION
EP3790979A4 (en) RELEASE OF ADENO-ASSOCIATED VIRUS (AAV) FROM ANTI-FAM19A5 ANTIBODIES
EP3851456A4 (en) ANTI-CD38 ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL APPLICATION
MX2021006360A (es) Composicion farmaceutica de anticuerpo cd40 y uso de la misma.
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
EP3647323A4 (en) ANTI-GITR ANTIBODIES, ANTIGEN BINDING FRAGMENT AND ASSOCIATED PHARMACEUTICAL USE
EP4006055A4 (en) ANTI-BCMA ANTIBODIES, ANTIGEN-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
EP4067495A4 (en) CONSTRUCTION OF mRNA FOR PROTEIN EXPRESSION AND ASSOCIATED USE
MX2022006750A (es) Inhibidores de masp-2 y metodos de uso.
EP3919516A4 (en) ANTI-CD79B ANTIBODY, ANTIGEN-BINDING FRAGMENT THEREOF AND PHARMACEUTICAL USE THEREOF
MX2020010092A (es) Variantes de anticuerpo c-terminales.
CR20220322A (es) Formulaciones de anticuerpos anti-pd-l1